| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.panaceabiotec.com | |
| Market Cap | 836.38 Cr. | |
| Enterprise Value(EV) | 709.17 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -1.99 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 40.73 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 137.92 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 0.99 | Calculated using Price: 136.55 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 6.13 Cr. | 61,250,746 Shares |
| FaceValue | 1 | |
| About Panacea Biotec Ltd. | ||
| The company has product portfolio that's caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal. Business Areas of the Company :- (1) Research and Development (R&D) – Under this the company primarily focuses on New Chemical Entities (NCE), New Biological Entities (NBE) and Novel Drug Delivery System (NDDS). (2) Vaccines- Under this the company has product portfolio of oral polio vaccines and Hepatitis-B vaccines. (3) Formulations- It has created flagship brands like Willgo for pain management, Glizid & Glizid-M for diabetes; Panimun Bioral and Mycept for kidney transplant. | ||
| 1 Day |
|
-0.47% |
| 1 Week |
|
-6.37% |
| 1 Month |
|
-0.15% |
| 3 Month |
|
-19.94% |
| 6 Month |
|
-17.75% |
| 1 Year |
|
+12.84% |
| 2 Year |
|
-21.64% |
| 5 Year |
|
-32.23% |
| 10 Year |
|
-8.96% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -253.03 | 0 | -34.38 | -22.94 | 11.39 | -75.26 | 0 | 332.85 | -3.92 | |
| Return on Capital Employed (%) | 0.45 | 9.93 | 2.76 | 2.63 | 13.44 | -0.38 | 5.36 | 217.12 | 1.94 | |
| Return on Assets (%) | -4.87 | -1.01 | -2.97 | -4.53 | 2.55 | -13.36 | -10.69 | 74.05 | -2.24 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 471 | 449 | 356 | 309 | 350 | 199 | -229 | 877 | 844 | 847 | |
| Non Curr. Liab. | 918 | 1,100 | 719 | 591 | 70 | 741 | 960 | 85 | 99 | 97 | |
| Curr. Liab. | 706 | 475 | 689 | 696 | 938 | 622 | 447 | 774 | 330 | 332 | |
| Minority Int. | 3 | 1 | 11 | -3 | -3 | -3 | -3 | -3 | -3 | -4 | |
| Equity & Liab. | 2,099 | 2,025 | 1,774 | 1,592 | 1,356 | 1,559 | 1,177 | 1,735 | 1,271 | 1,272 | |
| Non Curr. Assets | 1,573 | 1,475 | 1,071 | 1,028 | 848 | 875 | 666 | 745 | 703 | 737 | |
| Curr. Assets | 526 | 549 | 703 | 565 | 508 | 683 | 474 | 951 | 562 | 535 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 2,099 | 2,025 | 1,774 | 1,592 | 1,356 | 1,559 | 1,177 | 1,735 | 1,271 | 1,272 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 687 | 653 | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 552 | |
| Other Income | 28 | 20 | 47 | 8 | 5 | 30 | 10 | 11 | 52 | 30 | |
| Total Income | 716 | 673 | 591 | 601 | 462 | 574 | 635 | 672 | 512 | 582 | |
| Total Expenditure | -643 | -541 | -497 | -508 | -590 | -519 | -548 | -674 | -558 | -571 | |
| PBIDT | 72 | 132 | 94 | 93 | -128 | 56 | 87 | -2 | -46 | 10 | |
| Interest | -105 | -127 | -101 | -101 | -105 | -174 | -185 | -181 | -4 | -4 | |
| Depreciation | -67 | -73 | -68 | -59 | -55 | -44 | -46 | -44 | -39 | -37 | |
| Taxation | -3 | -2 | 11 | -10 | -9 | -17 | -2 | -371 | -47 | -34 | |
| Exceptional Items | 50 | 8 | 334 | -15 | 1,676 | 103 | 53 | ||||
| PAT | -102 | -21 | -56 | -76 | 38 | -195 | -146 | 1,078 | -34 | -12 | |
| Minority Interest | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 1 | ||
| Share Associate | -6 | 0 | 0 | 0 | 0 | 0 | |||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | -107 | -18 | -54 | -74 | 38 | -194 | -148 | 1,078 | -33 | -12 | |
| Adjusted EPS | -17 | -3 | -9 | -12 | 6 | -32 | -24 | 176 | -5 | -2 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 54 | 37 | 91 | 131 | 118 | 105 | -30 | 107 | -108 | -422 | |
| Cash Fr. Inv. | -38 | -37 | 16 | -26 | 55 | -5 | -35 | -48 | 1,283 | 430 | |
| Cash Fr. Finan. | -30 | -1 | -117 | -107 | -164 | -101 | 91 | -47 | -1,176 | -18 | |
| Net Change | -14 | -1 | -10 | -2 | 9 | -2 | 26 | 12 | -2 | -10 | |
| Cash & Cash Eqvt | 21 | 20 | 10 | 7 | 16 | 14 | 40 | 52 | 50 | 40 |
|
Sat, 13 Apr 2024
Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Financial Year Ended March 31 2024 We are enclosing herewith the certified copy of certificate received from M/s R&D Company Secretaries for the financial year ended March 31 2024 confirming that all Letter of Confirmation(s) have been issued by the Company within the stipulated time from the date of lodgement for sub-division consolidation renewal exchange or endorsement of calls/allotment of monies change of name as the case may be. |
|
Fri, 05 Apr 2024
Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 For The Financial Year Ended On March 31 2024 We are enclosing herewith the certificate duly signed by Skyline Financial Services Pvt. Ltd. RTA and Company Secretary of the Company for the financial year ended on March 31 2024 in compliance of Regulation 7(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
|
Fri, 05 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 We are enclosing herewith a certificate dated April 03 2024 issued by Skyline Financial Services Pvt. Ltd. RTA of the Company confirming compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended March 31 2024. |
| Fri, 19 Apr 2024 |
Closing Below Previous Low
|
Making Lower Lows for 2 Days
|
High Decrease in 3 Months
|
CCI Trending Down
|
Close Crossing 20 SMA From Above
|
